Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

322 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
Pepper C, Majid A, Lin TT, Hewamana S, Pratt G, Walewska R, Gesk S, Siebert R, Wagner S, Kennedy B, Miall F, Davis ZA, Tracy I, Gardiner AC, Brennan P, Hills RK, Dyer MJ, Oscier D, Fegan C. Pepper C, et al. Among authors: oscier d. Br J Haematol. 2012 Feb;156(4):499-507. doi: 10.1111/j.1365-2141.2011.08974.x. Epub 2011 Dec 15. Br J Haematol. 2012. PMID: 22171799 Free article.
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity.
Davis Z, Forconi F, Parker A, Gardiner A, Thomas P, Catovsky D, Rose-Zerilli M, Strefford JC, Oscier D. Davis Z, et al. Among authors: oscier d. Br J Haematol. 2016 Apr;173(1):127-36. doi: 10.1111/bjh.13940. Epub 2016 Feb 5. Br J Haematol. 2016. PMID: 26846718 Free article. Clinical Trial.
The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors.
Malcikova J, Stalika E, Davis Z, Plevova K, Trbusek M, Mansouri L, Scarfò L, Baliakas P, Gardiner A, Sutton LA, Francova HS, Agathangelidis A, Anagnostopoulos A, Tracy I, Makris A, Smardova J, Ghia P, Belessi C, Gonzalez D, Rosenquist R, Oscier D, Pospisilova S, Stamatopoulos K. Malcikova J, et al. Among authors: oscier d. Br J Haematol. 2014 Aug;166(4):621-5. doi: 10.1111/bjh.12893. Epub 2014 Apr 12. Br J Haematol. 2014. PMID: 24725250 Free article. No abstract available.
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T. Pratt G, et al. Among authors: oscier d. Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23. Br J Haematol. 2018. PMID: 28643365 Free article. Clinical Trial. No abstract available.
t(8;9) in chronic myeloid leukaemia.
Oscier DG, Gardiner A, Dyer M. Oscier DG, et al. Br J Haematol. 1993 Jan;83(1):176-7. doi: 10.1111/j.1365-2141.1993.tb04653.x. Br J Haematol. 1993. PMID: 8435330 No abstract available.
322 results